87 related articles for article (PubMed ID: 29327347)
1. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
Nair JR; Caserta J; Belko K; Howell T; Fetterly G; Baldino C; Lee KP
Leukemia; 2017 Aug; 31(8):1715-1726. PubMed ID: 28008178
[TBL] [Abstract][Full Text] [Related]
3. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.
Lu J; Zavorotinskaya T; Dai Y; Niu XH; Castillo J; Sim J; Yu J; Wang Y; Langowski JL; Holash J; Shannon K; Garcia PD
Blood; 2013 Aug; 122(9):1610-20. PubMed ID: 23818547
[TBL] [Abstract][Full Text] [Related]
4. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
[TBL] [Abstract][Full Text] [Related]
5. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
Int J Biol Macromol; 2024 May; 270(Pt 1):132030. PubMed ID: 38704069
[TBL] [Abstract][Full Text] [Related]
6. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
Maruhashi T; Miki H; Sogabe K; Oda A; Sumitani R; Oura M; Takahashi M; Harada T; Fujii S; Nakamura S; Kurahashi K; Endo I; Abe M
Int J Hematol; 2024 Mar; 119(3):291-302. PubMed ID: 38252236
[TBL] [Abstract][Full Text] [Related]
7. Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation.
Chen X; Zhao J; Chen R; Shen L; Lu J; Guo Y; Chi X; Geng S; Zhang Q; Pan Z; He X; Xu L; Shen Z; Yang H; Lei T
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300516. PubMed ID: 38263717
[TBL] [Abstract][Full Text] [Related]
8. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Mar; ():. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
9. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
[TBL] [Abstract][Full Text] [Related]
10. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
11. YM155 exerts potent cytotoxic activity against quiescent (G
Ookura M; Fujii T; Yagi H; Ogawa T; Kishi S; Hosono N; Shigemi H; Yamauchi T; Ueda T; Yoshida A
Oncotarget; 2017 Dec; 8(67):111535-111550. PubMed ID: 29340073
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Fouquet G; Karlin L; Macro M; Caillot D; Roussel M; Arnulf B; Pegourie B; Petillon MO; Mathiot C; Hulin C; Kolb B; Stoppa AM; Brechiniac S; Rodon P; Dib M; Tiab M; Richez V; Araujo C; Wetterwald M; Garderet L; Royer B; Perrot A; Benboubker L; Decaux O; Escoffre-Barbe M; Fermand JP; Moreau P; Avet-Loiseau H; Attal M; Facon T; Leleu X
Ann Hematol; 2018 May; 97(5):831-837. PubMed ID: 29330561
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
14. STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.
Jung SH; Ahn SY; Choi HW; Shin MG; Lee SS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Blood Res; 2017 Dec; 52(4):293-299. PubMed ID: 29333406
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Sahebi F; Iacobelli S; Sbianchi G; Koster L; Blaise D; Reményi P; Russell NH; Ljungman P; Kobbe G; Apperley J; Trneny M; Krejci M; Wiktor-Jedrzejczak W; Sanchez JF; Schaap N; Isaksson C; Lenhoff S; Browne P; Scheid C; Wilson KMO; Yakoub-Agha I; Muñiz SG; Schönland S; Morris C; Garderet L; Kröger N
Biol Blood Marrow Transplant; 2018 May; 24(5):930-936. PubMed ID: 29339268
[TBL] [Abstract][Full Text] [Related]
16. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y; Lairson DR; Chan W; Du XL
Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA
Blood Cancer J; 2018 Jan; 8(1):7. PubMed ID: 29330358
[TBL] [Abstract][Full Text] [Related]
18. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
20. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.
Pandit A; Leblebjian H; Hammond SP; Laubach JP; Richardson PG; Baden LR; Marty FM; Issa NC
Bone Marrow Transplant; 2018 Jul; 53(7):942-945. PubMed ID: 29426830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
